Sponsor
Amal Therapeutics S.A.
Avenue De La Roseraie 64, 1205
About the sponsor
Research activity is centered on pancreatic ductal adenocarcinoma with a specific focus on tumors carrying KRAS G12D and KRAS G12V mutations. The sponsor’s clinical work is aligned with vaccine-based immunotherapy for patients with mutated pancreatic cancer.
- KRAS-mutated pancreatic ductal adenocarcinoma
- Vaccine-based immunotherapy
- Mutated pancreatic cancer
The trial portfolio reflects interest in tumor-specific immune targeting within a highly aggressive gastrointestinal malignancy.
Try clearing a filter, or search the whole catalogue.
Are you running a clinical trial?
Increase visibility for your trials and help patients find your site through our platform.